Curis (NASDAQ:CRIS) Earns Buy Rating from HC Wainwright

Curis (NASDAQ:CRIS)‘s stock had its “buy” rating reaffirmed by research analysts at HC Wainwright in a research report issued to clients and investors on Friday,Benzinga reports. They currently have a $17.00 price objective on the biotechnology company’s stock.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Curis in a research note on Wednesday, January 21st. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $17.00.

Curis Stock Down 7.1%

Shares of NASDAQ CRIS opened at $0.76 on Friday. Curis has a 12-month low of $0.75 and a 12-month high of $3.13. The firm’s 50-day simple moving average is $0.98 and its 200 day simple moving average is $1.26. The company has a market cap of $10.39 million, a price-to-earnings ratio of -0.21 and a beta of 3.02.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in CRIS. Jane Street Group LLC grew its position in shares of Curis by 71.8% during the 4th quarter. Jane Street Group LLC now owns 25,323 shares of the biotechnology company’s stock worth $25,000 after buying an additional 10,586 shares during the period. XTX Topco Ltd acquired a new position in Curis in the fourth quarter valued at approximately $26,000. Warberg Asset Management LLC bought a new position in Curis in the third quarter valued at approximately $73,000. Squarepoint Ops LLC grew its holdings in Curis by 46.2% during the 4th quarter. Squarepoint Ops LLC now owns 86,483 shares of the biotechnology company’s stock worth $85,000 after acquiring an additional 27,343 shares during the period. Finally, Focused Wealth Management Inc grew its holdings in Curis by 33.8% during the 3rd quarter. Focused Wealth Management Inc now owns 79,199 shares of the biotechnology company’s stock worth $131,000 after acquiring an additional 19,995 shares during the period. 29.97% of the stock is currently owned by institutional investors and hedge funds.

Curis Company Profile

Curis, Inc is a biotechnology company focused on the discovery, development and commercialization of targeted small molecule and antibody therapeutics for the treatment of cancer. The company’s research centers on exploiting key signaling pathways and tumor microenvironment interactions to develop compounds with the potential to address unmet medical needs. Curis’ proprietary pipeline includes multiple programs at various stages of clinical and preclinical development, reflecting its emphasis on innovative oncology drug candidates.

Among Curis’ lead assets is CA-4948, an oral inhibitor of interleukin-1 receptor–associated kinase 4 (IRAK4) partnered with Ikena Oncology, which is being evaluated in hematologic malignancies and solid tumors.